MARC, a novel modular chimeric antigen receptor, improves T cell-based cancer immunotherapies by preventing early T cell exhaustion and enhancing persistence
MARC, a novel modular chimeric antigen receptor, improves T cell-based cancer immunotherapies by preventing early T cell exhaustion and enhancing persistence
Blog Article
Background Chimeric antigen receptor T cell (CAR-T)-based immunotherapies have reshaped the therapeutic landscape of cancer treatment, in particular for iphone 14 price miami patients afflicted with leukemia.However, defects in CAR behaviors and clinical complications have hindered their widespread application across diverse cancer types.Chief among these defects is high tonic signaling, absent in native activating immune receptors, which accelerates T cell exhaustion and undermines treatment efficacy.
We hypothesized that these limitations arise because current CAR architectures fail to replicate the modular design of native activating immune receptors, which integrate distinct receptor and signaling modules.This modular assembly is crucial for maintaining proper receptor regulation and function.Methods Therefore, we set forth to develop a modular chimeric antigen receptor leveraging the same assembly principles found in native activating immune receptors to reestablish the intrinsic safeguards in receptor expression and signaling.
Results The resulting Modular Actuation Receptor Complex (MARC) displayed surface expression levels akin to its native immune receptor counterpart, the NK cell receptor KIR2DS3, while eliminating tonic signaling.In a clinically relevant mouse leukemia model, MARC-T cells exhibited remarkable long-term persistence and a getpureroutine.com less exhausted phenotype compared with conventional CAR-T cells.Conclusions With its modular architecture, the MARC offers unparalleled opportunities for optimization and broad applicability across different cell types, paving the way for transformative advancements in cell-based therapies.
This innovation holds immense promise as a next-generation therapeutic tool in clinical settings.